Objective: To determine if a missense change at codon 64 of ADRB3 (Trp64Arg), a candidate obesity gene, is associated with obesity and levels of subcutaneous or visceral fat in African-American breast cancer cases. Several observational studies have found that women, who are overweight or obese at the time of diagnosis, as well as those who gain weight after diagnosis, are at greater risk for breast cancer recurrence and death than non-overweight women. Design: Prospective cohort of breast cancer cases. Subjects: 219 African-American breast cancer patients participating in the Los Angeles component of the Health, Eating, Activity and Lifestyle Study. Measures: ADRB3 Trp64Arg genotype, measures of weight including body mass index (BMI), weight gain (weight 5 years before diagnosis compared with weight at 30 months after diagnosis), obesity (BMIX30 kg/m 2 ), waist/hip circumference and visceral or subcutaneous fat were determined by magnetic resonance imaging. Results: African-American women who were homozygous for the ADRB3 wild-type allele had significantly higher mean visceral fat levels than women who carried the variant (P ¼ 0.04), and were significantly more likely to be obese (odd ratios (OR) ¼ 2.1, 95% confidence interval (CI) ¼ 1.1-4.2). The association with obesity was most pronounced among women who were premenopausal (OR ¼ 4.8, 95% CI ¼ 1.3-18), who received chemotherapy for their breast cancer (OR ¼ 6.1, 95% CI ¼ 1.8-20), or who were not physically active (OR ¼ 3.9, 95% CI ¼ 1.5-9.7). Conclusion: The wild-type allele of the ADRB3 missense change was associated with measures of obesity in our sample of African-American women. The association was modified by menopausal status, history of chemotherapy and modest levels of physical activity. These results will need to be confirmed in an independent sample.
Introduction
Breast cancer is the most common cancer in women as well as the second leading cause of cancer deaths. 1 One important predictor of breast cancer prognosis for women is weight. 2 Several observational studies have found that women who are overweight or obese at the time of breast cancer diagnosis, as well as those who gain weight after diagnosis, are at greater risk for breast cancer recurrence and death than nonoverweight women. [2] [3] [4] [5] [6] The relationship between obesity and breast cancer may be explained, at least in part, by women's lifetime exposure to estrogens. Premenopausal obesity has been associated with lower breast cancer risk, presumably because obesity is associated with menstrual cycle disturbances including secondary amenorrhea, 7 whereas postmenopausal obesity has been associated with an increased risk of breast cancer, attributed to greater estrogen biosynthesis in peripheral adipose tissue. 8 There is some evidence that weight-control measures such as physical activity may improve survival in women diagnosed with breast cancer, and therefore, genetic determinants of weight or weight gain may also be important determinants of survival in breast cancer patients. Family studies suggest that human obesity has both environmental and genetic determinants. 9, 10 Efforts to identify candidate obesity genes have focused on genes active in adipose tissue owing to the crucial role of the adipose cells in regulating the storage and mobilization of lipids. One such gene, ADRB3, has been targeted as a candidate obesity gene because of its role in the regulation of lipolysis and thermogenesis. 11 The ADRB3 gene is highly conserved between humans and rodents and its functional impairment may lead to obesity by altering metabolic processes of fat tissue. 11, 12 The receptor is expressed in visceral and subcutaneous fat tissue, but is more abundant and active in visceral tissue. 11 A missense change at codon 64 of this gene (Trp64Arg) has been identified and has been associated with measures of obesity, [12] [13] [14] weight gain, 15 insulin resistance 13 and type II diabetes. 12 In the current study, we examined the association between the codon 64 ADRB3 missense change and measures of weight and obesity among African-American breast cancer patients. We assessed the relationship of the ADRB3 genotypes with visceral and subcutaneous abdominal fat, body mass index (BMI), weight change and measures of central obesity (waist, hip, waist-to-hip ratio (WHR)) approximately 30 months after diagnosis of breast cancer, when most women had finished their primary cancer treatment. The analysis was completed to understand better the determinants of weight in breast cancer patients, an important predictor of disease-free and total survival.
Materials and methods
The analysis included 219 breast cancer patients (approximately 30 months after diagnosis) from the Los Angeles component of the Health, Eating, Activity, and Lifestyle (HEAL) Study, a population-based prospective cohort study of women with breast cancer; the analysis was restricted to Los Angeles participants because collection of magnetic resonance imaging (MRI) data for determination of visceral and subcutaneous fat was exclusive to the Los Angeles site. The HEAL study includes 1183 pre-and postmenopausal breast cancer patients from California, Washington and New Mexico, 16 and was designed to evaluate the roles of hormones, genetics, diet, weight change and physical activity on breast cancer prognosis and survival. [17] [18] [19] Women were recruited into the HEAL Study through Surveillance, Epidemiology and End Results (SEER) registries in New Mexico, Los Angeles County (CA) and Western Washington. Details of the aims, study design and recruitment procedures have been published previously. 19 Participants for the Los Angeles component of the HEAL study were 366 African-American women with in situ, localized or regional breast cancer who had participated in the Los Angeles portion of the Women's Contraceptive and Reproductive Experiences (CARE) Study, a case-control study of invasive breast cancer, or who had participated in a parallel case-control study of in situ breast cancer (INSITU). Eligible participants from these two studies were women, who were diagnosed with breast cancer between May 1995 and May 1998, who were aged between 35 and 64 years at diagnosis, and who were born in the United States and therefore able to speak English. 18 Participation in the HEAL study included completion of an in-person interview conducted 24 months following the CARE or INSITU study interviews.
The analysis was restricted to 219 African-American women, who had provided a blood sample for genetic analysis and who had completed anthropometric and questionnaire data. Of the original 366 women who were eligible, 105 women were excluded because they did not complete a 24-month follow-up interview; reasons included death (n ¼ 19), illness (n ¼ 2), moved out of study area (n ¼ 16), refused to participate (n ¼ 29) or never reached for a second interview (n ¼ 39). An additional 42 women who completed the interview were excluded for missing covariate history including missing weight (n ¼ 1), missing hip and waist measurements (n ¼ 9), no blood sample (n ¼ 29) and missing fat-free mass and percent body fat measurements (n ¼ 3).
The Los Angeles component of the study was performed after receiving approval by the Institutional Review Board at the University of Southern California.
Data collection and definitions

Questionnaire variables
Questionnaire data for HEAL were collected during in-person interviews conducted 24 months (approximately 30 months after breast cancer diagnosis) following the CARE or INSITU baseline study interviews. Baseline information was collected on demographics, reproductive and menstrual history (age at menarche, regularity of periods when menstruating, age at menopause, type of menopause), hysterectomy and oophorectomy status, history of oral contraceptive and hormone replacement therapy use, family history of breast cancer and other diseases, history of tobacco and alcohol use, maximal adult height, height at age 18 and 65, and previous weight (ages 18, 35, 50 , 65 years and 5 years before diagnosis). The HEAL 24-month follow-up interview included information on tobacco and alcohol use, menopausal status, physical activity, medical problems including diabetes, anthropometric measurements and cancer treatment history. Treatment information, including chemotherapy and tamoxifen history, was obtained by self-report, by examining medications used at the time of the interview and by abstracting each patient's medical records. Los Angeles participants were also asked to undergo MRI to measure abdominal fat. Further details on measures of physical activity, anthropometrics and MRI are described below.
Physical activity assessment
The HEAL physical activity questionnaire was based on the Modifiable Activity Questionnaire developed by Kriska Health Organization definition of obesity. 22 Waist and hip measurements were taken at the time of each woman's MRI appointment or at the patient's home if the respondent refused the MRI. Waist circumference was measured in centimeters just above the superior margin of the iliac crest. Hip circumference was measured in centimeters at the maximal posterior projection of the buttocks. 19 All measurements were completed by one trained USC (the University of Southern California) interviewer. MRI was completed at the Los Angeles County -USC Imaging Science Center; single-slice T1-weighted images with 1 cm thickness were acquired axially at the umbilicus. Inter-abdominal fat and extra-abdominal fat was outlined and recorded in square centimeters as determined by the study radiologist (Dr Pat Colletti), and image results were archived in electronic and film formats. Inter-abdominal and extra-abdominal fat measurements were reviewed and confirmed by a second radiologist at the University of New Mexico.
Blood draw, DNA extraction and polymorphism determination Fasting blood samples (35 ml) were obtained from each participant at the time of the HEAL interview. Blood was processed within 3 h of collection; serum and buffy coat were stored in 1.8-ml aliquot tubes at À70 to À801C. Genomic DNA was extracted from peripheral blood leukocytes using a Qiagen kit. The ADRB3 Trp64Arg variant for all samples was determined by allelic discrimination in a fluorogenic Taqman assay at Albany Molecular Research (Bothell, Washington, DC, USA) with the ABI 7700 Sequence Detection System (Applied Biosystems, Foster City, CA, USA), which has been described. 23 The polymerase chain reaction (PCR) primers were (sense) 5 0 -GGCCATCGCC-3 0 and (antisense) 5 0 -GG ACTCCGAG-3 0 . The sense and antisense PCR primers were used at a final concentration of 900 nM in 25 ml PCR solution. Both fluorogenic wild-type and variant allele-specific probes were complementary to their corresponding antisense strands and were labeled with the 6-carboxy tetramethylrhodamine (TAMRA) quencher at the 3 0 end, with the 6-FAM (6-carboxy fluorescein) reporter dye and the VIC reporter dye at the 5 0 end. The wild-type and variant fluorogenic probes were used at a final concentration of 100 nM and detected alleles from approximately 40 ng of genomic DNA template. Temperature cycling was performed as followed: 501C for 2 min and 951C for 10 min, followed by 40 cycles of 951C for 15 s and 621C for 1 min. The data were collected and analyzed with ABI Prism 7700 Sequence Detection System, version 1.6.5. All Taqman genotyping calls were confirmed by sequencing several samples of each allele.
Stage of disease
Stage of disease is coded from medical records and retained as part of the Los Angeles County Cancer Surveillance Program (CSP) database. The CSP has been a National Cancer Institute-funded SEER registry since 1992 and is estimated to be more than 99% complete. Participants were classified as having in situ, stage I (localized) or stage II-IIIA (regional) breast cancer using the SEER stage of disease classification.
Statistical analyses
Statistical analyses were performed on logarithmically transformed values of weight, BMI, and abdominal fat and geometric mean values with 95% CI are presented. Analysis of covariance was used to test the hypotheses that mean visceral abdominal fat, subcutaneous abdominal fat, BMI, weight gain from 5 years before diagnosis to the 24-month follow-up interview, and mean hip and waist circumference vary by ADRB3 genotype. OR and 95% CI were calculated using unconditional logistic regression to determine if the ADRB3 genotype was associated with obesity status (defined as having a BMIX30 kg/m 2 ). All final models were adjusted for age at baseline interview. Adjustment for other potential determinants of obesity was considered, including physical activity, menopausal status at baseline and 24-month interviews, smoking history, history of chemotherapy, tamoxifen therapy, usual weight (i.e. weight 5 years before diagnosis) and diabetes. These variables were not included in the final model as they did not substantially affect our results. Because ADRB3 has been associated with diabetes in some studies, a subanalysis excluding women with a history of diabetes was completed. Stratum-specific estimates were calculated using product ADRB3 and obesity R McKean-Cowdin et al terms to evaluate potential effect modification separately by menopausal status at baseline and 24-month interviews (pre-/postmenopausal), history of chemotherapy (ever versus never), moderate/vigorous physical activity (above and below median MET value), smoking history (current, past, never), tamoxifen therapy (yes/no) and radiation therapy (yes/no). Wald tests were used to determine P-values for interaction for PROC LOGISTIC procedure. T-test were used to determine P-values for interaction for PROC GLM procedure. Calculations were performed in SAS Version 8.2 (SAS Institute, Cary, NC, USA).
Results
The mean age at the baseline interview (approximately 6 months after diagnosis) of the 219 breast cancer survivors in the analysis was 51 years ( African-American patients who carried the ADRB3 homozygous wild-type allele had significantly higher geometric mean levels of visceral abdominal fat than women who carried the variant allele (P ¼ 0.04); geometric mean levels of subcutaneous abdominal fat did not differ by ADRB3 genotype (P ¼ 0.50) ( Table 2) . Differences in hip circumference, waist circumference and WHR also did not differ by ADRB3 genotype (data not shown).
We examined the association between ADRB3 genotype and BMI, where BMI was classified obese (BMIX30 kg/m Table 3 ). This association was most pronounced among women who were premenopausal (OR ¼ 4.8, 95% CI ¼ 1.3-18.1), who were less physically active (OR ¼ 3.9, 95% CI ¼ 1.5-9.7) or who had been treated with chemotherapy (OR ¼ 6.1, 95% CI ¼ 1.8-20.4); the associations by menopausal status, chemotherapy and physical activity were independent. No differences in association were found by smoking, tamoxifen or radiation therapy history.
When we examined the association between ADRB3 and geometric mean BMI, we found that mean BMI was slightly higher for homozygous carriers of the ADRB3 wild-type allele than for carriers of the variant (P ¼ 0.15) ( Table 4 ). Similar to our findings for obesity (BMIX30 kg/m 2 ), the association between ADRB3 genotype and geometric mean BMI was statistically significant when restricted to premenopausal women (P ¼ 0.03), women who had received chemotherapy (P ¼ 0.04) or women who were less physically active (P ¼ 0.01). Change in mean BMI from 5 years before diagnosis to the 24-month follow-up interview was slightly, although not statistically significantly, higher for homozygous carriers of the ADRB3 wild-type allele than carriers of the variant (wild-type BMI change 3.3, 95% CI ¼ 2.6-3.9 vs variant BMI change 2.8, 95% CI ¼ 1.7-4.0, P ¼ 0.53). None of our results changed after adjusting for a history of diabetes or excluding these women from the analyses (n ¼ 34). 
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Discussion
In this sample of African-American breast cancer survivors, we found that the Trp64Arg substitution in ADRB3 was associated with reduced measures of adiposity. Specifically, we found that women who were homozygous for ADRB3 wild-type allele had significantly higher levels of visceral abdominal fat compared with women who carried the variant. Further, women with the wild-type allele were more likely to be obese. This association was strongest among premenopausal women, women who had been treated with chemotherapy or who were less physically active; however, the numbers of women in each stratum were small. We did not find significant associations for ADRB3 with other measures of weight, including weight gain, waist circumference, hip circumference or WHR. The 12.3% minor allele (A) frequency in our AfricanAmerican sample is similar to the frequency reported for other African-American (12%) and Mexican-American populations (13%), but higher than the frequency reported 
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for Caucasians (8%) and lower than the frequency reported for Pima Indians (31%). 24 In previous epidemiologic studies, the association between the ADRB3 variant and obesity-related phenotypes has been investigated among individuals from several racial/ ethnic groups and nationalities, including Caucasians, 13 Japanese, 12, 25, 26 Pima Indians, 24 Mexican Americans, 14 African Americans 27,28 and Jamaicans. 29 Previous studies of white or Japanese populations found the variant allele of the ADRB3 receptor to be associated with elevated measures of obesity, 13 whereas two previous studies of African Americans reported associations with the wild-type receptor. Consistent with our data, Lowe Jr et al. 27 reported a protective association between the variant allele and BMI among African-American women (P ¼ 0.04). Similarly, Terra et al.
28
reported that African Americans who were homozygous for the wild-type allele had higher mean BMI than variant carriers, although the association did not reach statistical significance. In contrast, McFarlane-Anderson et al. 29 found
that Jamaican women who were carriers of the variant allele had a significantly increased BMI than women who were homozygous for the wild-type allele.
ADRB3 is a G-coupled protein receptor 30 that stimulates the mobilization of lipids from white fat cells and increases thermogenesis in brown fat cells. 31 The tryptophan-toarginine substitution at codon 64 of ADRB3 was initially reported in 1995. 13, 15, 24 The substitution is located in the first coding exon, at the junction of the first transmembrain domain and the first intracellular loop of the receptor.
32,33
The impact of the missense change is not known; it has been suggested that the substitution could impact receptorprotein folding or alter functional properties such as ligand binding or receptor activation. 32 The biochemical evidence that the substitution impairs receptor signaling is mixed. In vitro studies suggest the substitution does not impact ADRB3 receptor expression, its ability to bind andrenergic agonists or its activation in response to selective or non-selective agonists. 32 However, several studies found the maximal activation potential of cyclic AMP (adenosine 3 0 ,5 0 -cyclic monophosphate) in Arg variant cells was reduced, suggesting the substitution may alter the receptor's ability to interact with G protein. [31] [32] [33] In clinical studies, a significant reduction in receptor sensitivity to a beta3-agonist was found in adipocytes of Arg carriers, 34 whereas two studies observed no association with basal metabolic rate. 35, 36 The ADRB3 receptor is more abundant and active in visceral adipose tissue than subcutaneous adipose. 11, [37] [38] [39] The high expression and activity of ADRB3 in visceral adipose tissue is consistent with our observed association between the ADRB3 variant and visceral, but not subcutaneous fat. Findings from a previous study of Japanese women 40 also indicated a significant association between the ADRB3 Trp64Arg substitution and visceral abdominal fat. In our African-American cases, the positive association between ADRB3 and obesity was found for the wild-type receptor, and in Japanese women, the association was found for the variant. A third study (Quebec Family Study) found no association present between the missense change and abdominal visceral fat. 36 We found the association of ADRB3 and measures of obesity to be stronger among premenopausal than postmenopausal women. Pasquali et al. 41 also found an association of the ADRB3 gene and weight among premenopausal women, but not among postmenopausal women, whereas a study by McFarlane-Anderson et al. 29 found a strong association between ADRB3 and BMI among both pre-and postmenopausal women. The presence of a stronger association between the ADRB3 missense change and obesity in premenopausal women may be explained by the fact that the expression of ADRB3 is age-dependent and expression has been shown to decrease with age. 11 Studies also have found postmenopausal women to have significantly higher BMI 41 and significantly less fat-free mass [41] [42] [43] than premenopausal women, whereas others have reported the odds of being obese was similar for pre-and postmenopausal women. 44 In our sample of breast cancer cases, the association of ADRB3 and obesity was strongest among women with a history of chemotherapy. Higher chemotherapy-associated weight gain among breast cancer cases has been reported by HEAL investigators using data from the Washington and New Mexico sites. 17, 18 Previous studies have also found that women experience increasing levels of fat mass, percent body fat 45 and body weight 35, 46, 47 following adjuvant chemotherapy. This increase appears to occur shortly after diagnosis, typically within the first year and includes a larger increase in fat mass than weight gain associated with normal aging. This sarcopenic weight gain is believed to be, at least in part, because of decreased physical activity and possibly to metabolic changes. 17 One possible explanation is lower activity during the first year of diagnosis due to nausea and fatigue following therapy. This difference was not observed in our sample of African-American breast cancer cases, as women who were treated with chemotherapy reported similar levels of moderate and vigorous physical activity (mean MET hours chemo ¼ 20.7; mean MET hours no chemo ¼ 19.9) at the 24-month follow-up interview as women who did not take chemotherapy. We did not collect physical activity history at the time of diagnosis and treatment, so it remains possible that women with chemotherapy gained weight because of lower activity at the time of their treatment. Physical activity has been shown to impact levels of visceral, subcutaneous and total body fat. [48] [49] [50] Accumulation of visceral fat, more so than accumulation in other parts of the body, has been of clinical concern because of its potential contribution to risk of chronic conditions including diabetes, hyperinsulinemia and hypertension, 51 and to risk of postmenopausal breast cancer because of the production of estrogens in adipose tissue. There is growing evidence that physical activity can decrease the risk of breast cancer [52] [53] [54] and suggestive evidence that physical activity after breast cancer diagnosis may improve survival. 55 In the current ADRB3 and obesity R McKean-Cowdin et al analysis, we found the association between the ADRB3 Trp genotype and obesity to be highest among sedentary women. Our finding that physical activity modifies the effect of ADRB3 on obesity is supported by data from the study of Spanish participants, 56 where risk of obesity was higher among carriers of the ADRB3 variant when restricted to sedentary people. Together, these data suggest that the association between ADRB3 gene and obesity may be altered by moderate levels of physical activity. Although we were able to detect an association between ADRB3 and measures of weight among HEAL AfricanAmerican breast cancer cases, these results may not be generalizable to other racial/ethnic groups. The associations for our African American set of cases and two other AfricanAmerican populations 27, 28 were found with the wild-type allele, whereas the ADRB3-weight association in white and Japanese populations has been described with the variant allele. Although some experimental studies suggest that carriers of the Arg variant may have reduced fat metabolism, the functional role of the missense is not yet established, nor do we know how lifestyle or other lipid metabolism pathway genes influence the ADRB3-weight association.
Further, nearly 46% of our population was obese, which may represent a group of individuals prone to weight gain owing genetic background or other individual characteristics. Another limitation of our study is that we collected weight at 24-months after diagnosis and at various ages before diagnosis (e.g. 5 years before diagnosis, age 35, age 18), but we did not measure weight or physical activity at the time of diagnosis so we could not examine changes from the time of diagnosis to the 24-month follow-up interview.
Conclusion
Several studies have reported an association between the codon 64 missense change of the ADRB3 gene and measures of weight. The results of the current study suggest that the wild-type allele of the ADRB3 codon 64 substitution is associated with higher measures of weight and obesity in our sample of African-American breast cancer cases. As our association was found with the opposite allele as reported in whites and the functionality of this change has not been clearly established, these findings will need to be confirmed in an independent set of African-American women. In our sample, the relationship between the ADRB3 gene and obesity was modified by menopausal status, history of chemotherapy and modest levels of physical activity. The physical activity finding suggests that whereas some women may be genetically predisposed to obesity, this tendency may be overcome with modest levels of exercise.
